Format

Send to

Choose Destination
Nat Med. 2015 May;21(5):431-9. doi: 10.1038/nm.3853.

Translational value of mouse models in oncology drug development.

Author information

1
Department of Molecular Oncology at Genentech, Inc., South San Francisco, California, USA.

Abstract

Much has been written about the advantages and disadvantages of various oncology model systems, with the overall finding that these models lack the predictive power required to translate preclinical efficacy into clinical activity. Despite assertions that some preclinical model systems are superior to others, no single model can suffice to inform preclinical target validation and molecule selection. This perspective provides a balanced albeit critical view of these claims of superiority and outlines a framework for the proper use of existing preclinical models for drug testing and discovery. We also highlight gaps in oncology mouse models and discuss general and pervasive model-independent shortcomings in preclinical oncology work, and we propose ways to address these issues.

PMID:
25951530
DOI:
10.1038/nm.3853
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center